Á lódáil...
Phase I Study of Pasireotide (SOM 230) and Everolimus (RAD001) in Advanced Neuroendocrine Tumors
Octreotide and everolimus have demonstrated efficacy in neuroendocrine tumors. Pasireotide is a somatostatin analog with binding affinity to a broader range of somatostatin receptor subtypes than octreotide. We performed a phase I study to evaluate the safety and feasibility of combining pasireotide...
Na minha lista:
| Foilsithe in: | Endocr Relat Cancer |
|---|---|
| Main Authors: | , , , , , , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
2012
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4469068/ https://ncbi.nlm.nih.gov/pubmed/22736724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-11-0382 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|